Relmada Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 26.32 million compared to USD 39.75 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 1.4 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | -1.32% | -1.64% | -27.54% |
05-08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.54% | 91.73M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023